Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 468

1.

Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.

Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, Berdeja J, Jabbour E, Issa JJ, Hao Y, Keer HN, Azab M, Savona MR.

Lancet Haematol. 2019 Jun;6(6):e317-e327. doi: 10.1016/S2352-3026(19)30029-8. Epub 2019 May 3.

PMID:
31060979
2.

Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.

Ragon BK, Odenike O, Baer MR, Stock W, Borthakur G, Patel K, Han L, Chen H, Ma H, Joseph L, Zhao Y, Baggerly K, Konopleva M, Jain N.

Clin Lymphoma Myeloma Leuk. 2019 Mar 26. pii: S2152-2650(18)31542-8. doi: 10.1016/j.clml.2019.03.015. [Epub ahead of print]

PMID:
31056348
3.

Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia.

Marks DI, Kebriaei P, Stelljes M, Gökbuget N, Kantarjian H, Advani AS, Merchant A, Stock W, Cassaday RD, Wang T, Zhang H, Loberiza F, Vandendries E, DeAngelo DJ.

Biol Blood Marrow Transplant. 2019 Apr 27. pii: S1083-8791(19)30267-8. doi: 10.1016/j.bbmt.2019.04.020. [Epub ahead of print]

4.

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.

Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, O'Brien SM, Jabbour E, Wang T, Liang White J, Sleight B, Vandendries E, Advani AS.

Cancer. 2019 Mar 28. doi: 10.1002/cncr.32116. [Epub ahead of print]

PMID:
30920645
5.

Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL.

Curran E, Stock W.

Blood. 2019 Apr 18;133(16):1715-1719. doi: 10.1182/blood-2018-12-852376. Epub 2019 Feb 22. Review.

PMID:
30796026
6.

N-Acyl Homoserine Lactone Derived Tetramic Acids Impair Photosynthesis in Phaeodactylum tricornutum.

Stock F, Syrpas M, Graff van Creveld S, Backx S, Blommaert L, Dow L, Stock W, Ruysbergh E, Lepetit B, Bailleul B, Sabbe K, De Kimpe N, Willems A, Kroth PG, Vardi A, Vyverman W, Mangelinckx S.

ACS Chem Biol. 2019 Feb 15;14(2):198-203. doi: 10.1021/acschembio.8b01101. Epub 2019 Feb 6.

PMID:
30694649
7.

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.

Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, Willman CL, Fulton N, Laumann KM, Malnassy G, Paietta E, Parker E, Geyer S, Mrózek K, Bloomfield CD, Sanford B, Marcucci G, Liedtke M, Claxton DF, Foster MC, Bogart JA, Grecula JC, Appelbaum FR, Erba H, Litzow MR, Tallman MS, Stone RM, Larson RA.

Blood. 2019 Apr 4;133(14):1548-1559. doi: 10.1182/blood-2018-10-881961. Epub 2019 Jan 18.

PMID:
30658992
8.

PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.

Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, Hagiwara K, Pelletier S, Gingras S, Berns H, Payne-Turner D, Hill A, Iacobucci I, Shi L, Pounds S, Cheng C, Pei D, Qu C, Newman S, Devidas M, Dai Y, Reshmi SC, Gastier-Foster J, Raetz EA, Borowitz MJ, Wood BL, Carroll WL, Zweidler-McKay PA, Rabin KR, Mattano LA, Maloney KW, Rambaldi A, Spinelli O, Radich JP, Minden MD, Rowe JM, Luger S, Litzow MR, Tallman MS, Racevskis J, Zhang Y, Bhatia R, Kohlschmidt J, Mrózek K, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Evans WE, Jeha S, Pui CH, Yang J, Paietta E, Downing JR, Relling MV, Zhang J, Loh ML, Hunger SP, Mullighan CG.

Nat Genet. 2019 Feb;51(2):296-307. doi: 10.1038/s41588-018-0315-5. Epub 2019 Jan 14.

PMID:
30643249
9.

Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin.

Jabbour E, Advani AS, Stelljes M, Stock W, Liedtke M, Gökbuget N, Martinelli G, O'Brien S, White JL, Wang T, Luisa Paccagnella M, Sleight B, Vandendries E, DeAngelo DJ, Kantarjian HM.

Am J Hematol. 2019 Apr;94(4):408-416. doi: 10.1002/ajh.25394. Epub 2019 Jan 17.

PMID:
30623490
10.

Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant.

Fan Y, Artz AS, van Besien K, Stock W, Larson RA, Odenike O, Godley LA, Kline J, Cunningham JM, LaBelle JL, Bishop MR, Liu H.

Exp Hematol Oncol. 2019 Jan 3;8:1. doi: 10.1186/s40164-018-0125-6. eCollection 2019.

11.

Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.

Wynne J, Wright D, Stock W.

Blood Adv. 2019 Jan 8;3(1):96-104. doi: 10.1182/bloodadvances.2018026211. Review.

12.

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).

Roboz GJ, Mandrekar SJ, Desai P, Laumann K, Walker AR, Wang ES, Kolitz JE, Powell BL, Attar EC, Stock W, Bloomfield CD, Kohlschmidt J, Mrózek K, Hassane DC, Garraway L, Jané-Valbuena J, Baltay M, Tracy A, Marcucci G, Stone RM, Larson RA.

Blood Adv. 2018 Dec 26;2(24):3608-3617. doi: 10.1182/bloodadvances.2018023689.

13.

Should immunologic strategies be incorporated into frontline ALL therapy?

Rank CU, Stock W.

Best Pract Res Clin Haematol. 2018 Dec;31(4):367-372. doi: 10.1016/j.beha.2018.09.015. Epub 2018 Sep 25. Review.

PMID:
30466749
14.

Treatment of Acute Promyelocytic Leukemia in Adults.

Osman AEG, Anderson J, Churpek JE, Christ TN, Curran E, Godley LA, Liu H, Thirman MJ, Odenike T, Stock W, Larson RA.

J Oncol Pract. 2018 Nov;14(11):649-657. doi: 10.1200/JOP.18.00328.

PMID:
30423270
15.

Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance).

Kutny MA, Geyer S, Laumann KM, Gregory J, Willman CL, Stock W, Larson RA, Powell BL, Feusner JH.

Pediatr Blood Cancer. 2019 Mar;66(3):e27542. doi: 10.1002/pbc.27542. Epub 2018 Nov 4.

PMID:
30393935
16.

Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation.

D'Angelo CR, Novitsky B, Mee Lee S, Godley LA, Kline J, Larson RA, Liu H, Odenike O, Stock W, Bishop MR, Artz AS.

Leuk Lymphoma. 2019 Mar;60(3):629-638. doi: 10.1080/10428194.2018.1493728. Epub 2018 Aug 2.

PMID:
30070150
17.

Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens.

Siegel SE, Advani A, Seibel N, Muffly L, Stock W, Luger S, Shah B, DeAngelo DJ, Freyer DR, Douer D, Johnson RH, Hayes-Lattin B, Lewis M, Jaboin JJ, Coccia PF, Bleyer A.

Am J Hematol. 2018 Oct;93(10):1254-1266. doi: 10.1002/ajh.25229. Epub 2018 Sep 3. Review.

PMID:
30058716
18.

Molecular Minimal Residual Disease Testing in Acute Myeloid Leukemia: A Review for the Practicing Clinician.

Hantel A, Stock W, Kosuri S.

Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):636-647. doi: 10.1016/j.clml.2018.06.017. Epub 2018 Jun 27. Review.

PMID:
30006258
19.

Environmental drivers and genomic architecture of trait differentiation in fire-adapted Banksia attenuata ecotypes.

He T, Lamont BB, Enright NJ, D'Agui HM, Stock W.

J Integr Plant Biol. 2019 Apr;61(4):417-432. doi: 10.1111/jipb.12697. Epub 2018 Nov 21.

PMID:
29993190
20.

Nematodes stimulate biomass accumulation in a multispecies diatom biofilm.

D'Hondt AS, Stock W, Blommaert L, Moens T, Sabbe K.

Mar Environ Res. 2018 Sep;140:78-89. doi: 10.1016/j.marenvres.2018.06.005. Epub 2018 Jun 5.

PMID:
29891387
21.

Can hydraulically redistributed water assist surrounding seedlings during summer drought?

Muler AL, van Etten EJB, Stock WD, Howard K, Froend RH.

Oecologia. 2018 Jul;187(3):625-641. doi: 10.1007/s00442-018-4158-7. Epub 2018 May 12.

PMID:
29752527
22.

Management of acute lymphoblastic leukemia in young adults.

Muffly LS, Reizine N, Stock W.

Clin Adv Hematol Oncol. 2018 Feb;16(2):138-146. Review.

PMID:
29741514
23.

Refractory Hypokalemia from Syndrome of Apparent Mineralocorticoid Excess on Low-Dose Posaconazole.

Wassermann T, Reimer EK, McKinnon M, Stock W.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e02605-17. doi: 10.1128/AAC.02605-17. Print 2018 Jul. No abstract available.

24.

Expanding the toolbox for cryopreservation of marine and freshwater diatoms.

Stock W, Pinseel E, De Decker S, Sefbom J, Blommaert L, Chepurnova O, Sabbe K, Vyverman W.

Sci Rep. 2018 Mar 9;8(1):4279. doi: 10.1038/s41598-018-22460-0.

25.

"Dar"-ing to target CD38 in T-ALL.

Wynne J, Stock W.

Blood. 2018 Mar 1;131(9):948-949. doi: 10.1182/blood-2018-01-826446. No abstract available.

26.

Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS.

Savona MR, Pollyea DA, Stock W, Oehler VG, Schroeder MA, Lancet J, McCloskey J, Kantarjian HM, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Cortes JE.

Clin Cancer Res. 2018 May 15;24(10):2294-2303. doi: 10.1158/1078-0432.CCR-17-2824. Epub 2018 Feb 20.

27.

Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review.

Siegel SE, Stock W, Johnson RH, Advani A, Muffly L, Douer D, Reed D, Lewis M, Freyer DR, Shah B, Luger S, Hayes-Lattin B, Jaboin JJ, Coccia PF, DeAngelo DJ, Seibel N, Bleyer A.

JAMA Oncol. 2018 May 1;4(5):725-734. doi: 10.1001/jamaoncol.2017.5305.

PMID:
29450465
28.

Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.

Jabbour EJ, DeAngelo DJ, Stelljes M, Stock W, Liedtke M, Gökbuget N, O'Brien S, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS, Kantarjian HM.

Cancer. 2018 Apr 15;124(8):1722-1732. doi: 10.1002/cncr.31249. Epub 2018 Jan 30.

29.

WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia.

Liu H, Zha Y, Choudhury N, Malnassy G, Fulton N, Green M, Park JH, Nakamura Y, Larson RA, Salazar AM, Odenike O, Gajewski TF, Stock W.

Exp Hematol Oncol. 2018 Jan 11;7:1. doi: 10.1186/s40164-018-0093-x. eCollection 2018.

30.

Management of important adverse events associated with inotuzumab ozogamicin: expert panel review.

Kebriaei P, Cutler C, de Lima M, Giralt S, Lee SJ, Marks D, Merchant A, Stock W, van Besien K, Stelljes M.

Bone Marrow Transplant. 2018 Apr;53(4):449-456. doi: 10.1038/s41409-017-0019-y. Epub 2018 Jan 12. No abstract available.

31.

A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.

Wang AY, Weiner H, Green M, Chang H, Fulton N, Larson RA, Odenike O, Artz AS, Bishop MR, Godley LA, Thirman MJ, Kosuri S, Churpek JE, Curran E, Pettit K, Stock W, Liu H.

J Hematol Oncol. 2018 Jan 5;11(1):4. doi: 10.1186/s13045-017-0550-8.

32.

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study.

DeAngelo DJ, Stock W, Stein AS, Shustov A, Liedtke M, Schiffer CA, Vandendries E, Liau K, Ananthakrishnan R, Boni J, Laird AD, Fostvedt L, Kantarjian HM, Advani AS.

Blood Adv. 2017 Jun 27;1(15):1167-1180. doi: 10.1182/bloodadvances.2016001925. eCollection 2017 Jun 27.

33.

Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL.

Kadri S, Lee J, Fitzpatrick C, Galanina N, Sukhanova M, Venkataraman G, Sharma S, Long B, Petras K, Theissen M, Ming M, Kobzev Y, Kang W, Guo A, Wang W, Niu N, Weiner H, Thirman M, Stock W, Smith SM, Nabhan C, Segal JP, Lu P, Wang YL.

Blood Adv. 2017 May 2;1(12):715-727. doi: 10.1182/bloodadvances.2016003632. eCollection 2017 May 9.

34.

Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults.

Tsai SB, Rhodes J, Liu H, Shore T, Bishop M, Cushing MM, Gergis U, Godley L, Kline J, Larson RA, Mayer S, Odenike O, Stock W, Wickrema A, van Besien K, Artz AS.

Biol Blood Marrow Transplant. 2018 May;24(5):997-1004. doi: 10.1016/j.bbmt.2017.12.794. Epub 2017 Dec 27.

35.

Progress in adult ALL: incorporation of new agents to frontline treatment.

Leonard J, Stock W.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):28-36. doi: 10.1182/asheducation-2017.1.28. Review.

36.

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.

Roboz GJ, Kantarjian HM, Yee KWL, Kropf PL, O'Connell CL, Griffiths EA, Stock W, Daver NG, Jabbour E, Ritchie EK, Walsh KJ, Rizzieri D, Lunin SD, Curio T, Chung W, Hao Y, Lowder JN, Azab M, Issa JJ.

Cancer. 2018 Jan 15;124(2):325-334. doi: 10.1002/cncr.31138. Epub 2017 Dec 6.

37.

Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia.

Hsu J, Artz A, Mayer SA, Guarner D, Bishop MR, Reich-Slotky R, Smith SM, Greenberg J, Kline J, Ferrante R, Phillips AA, Gergis U, Liu H, Stock W, Cushing M, Shore TB, van Besien K.

Biol Blood Marrow Transplant. 2018 Feb;24(2):359-365. doi: 10.1016/j.bbmt.2017.10.040. Epub 2017 Nov 8.

38.

A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001.

Uy GL, Mandrekar SJ, Laumann K, Marcucci G, Zhao W, Levis MJ, Klepin HD, Baer MR, Powell BL, Westervelt P, DeAngelo DJ, Stock W, Sanford B, Blum WG, Bloomfield CD, Stone RM, Larson RA.

Blood Adv. 2017 Jan 24;1(5):331-340. doi: 10.1182/bloodadvances.2016003053.

39.

De Novo Development of Bronchiectasis in Patients With Hematologic Malignancy.

Chen LW, McShane PJ, Karkowsky W, Gray SE, Adegunsoye A, Stock W, Artz A, White SR, Montner SM, Strek ME.

Chest. 2017 Sep;152(3):683-685. doi: 10.1016/j.chest.2017.06.042. No abstract available.

40.

Focus group study to identify the central facets of fear of hypoglycaemia in people with Type 2 diabetes mellitus.

Grammes J, Stock W, Mann CG, Flynn EM, Kubiak T.

Diabet Med. 2017 Dec;34(12):1765-1772. doi: 10.1111/dme.13506. Epub 2017 Oct 9.

PMID:
28856721
41.

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.

Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O'Connell CL, Tibes R, Walsh KJ, Podoltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri D, Stock W, Savona MR, Rosenblat TL, Berdeja JG, Ravandi F, Rock EP, Hao Y, Azab M, Issa JJ.

Lancet Oncol. 2017 Oct;18(10):1317-1326. doi: 10.1016/S1470-2045(17)30576-4. Epub 2017 Aug 24.

42.

In vitro assessment of the toxicity of bushfire emissions: A review.

Dong TTT, Hinwood AL, Callan AC, Zosky G, Stock WD.

Sci Total Environ. 2017 Dec 15;603-604:268-278. doi: 10.1016/j.scitotenv.2017.06.062. Epub 2017 Jun 17. Review.

PMID:
28628818
43.

Specialization to Extremely Low-Nutrient Soils Limits the Nutritional Adaptability of Plant Lineages.

Verboom GA, Stock WD, Cramer MD.

Am Nat. 2017 Jun;189(6):684-699. doi: 10.1086/691449. Epub 2017 Apr 3.

PMID:
28514635
44.

Genomic Scans across Three Eucalypts Suggest that Adaptation to Aridity is a Genome-Wide Phenomenon.

Steane DA, Potts BM, McLean EH, Collins L, Holland BR, Prober SM, Stock WD, Vaillancourt RE, Byrne M.

Genome Biol Evol. 2017 Feb 1;9(2):253-265. doi: 10.1093/gbe/evw290.

45.

Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.

Christ TN, Stock W, Knoebel RW.

J Oncol Pharm Pract. 2018 Jun;24(4):299-308. doi: 10.1177/1078155217701291. Epub 2017 Mar 29.

PMID:
28355969
46.

Counterpoint: Standard vs Investigational Agents as Upfront Treatment for High-Risk AML.

Brunner AM, Stock W.

Oncology (Williston Park). 2017 Mar 15;31(3):190, 192. No abstract available.

47.

Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.

Khan N, Hantel A, Knoebel RW, Artz A, Larson RA, Godley LA, Thirman MJ, Liu H, Churpek JE, King D, Odenike O, Stock W.

Leuk Lymphoma. 2017 Sep;58(9):1-7. doi: 10.1080/10428194.2017.1289524. Epub 2017 Feb 20.

PMID:
28278716
48.

Impact of treatment site on disparities in outcome among adolescent and young adults with Hodgkin lymphoma.

Wolfson J, Sun CL, Wyatt L, Stock W, Bhatia S.

Leukemia. 2017 Jun;31(6):1450-1453. doi: 10.1038/leu.2017.66. Epub 2017 Feb 20. No abstract available.

49.

Adolescents and Young Adults with Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia: Impact of Care at Specialized Cancer Centers on Survival Outcome.

Wolfson J, Sun CL, Wyatt L, Stock W, Bhatia S.

Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):312-320. doi: 10.1158/1055-9965.EPI-16-0722. Epub 2017 Feb 16.

50.

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ.

N Engl J Med. 2016 Nov 24;375(21):2023-2036. doi: 10.1056/NEJMoa1605949.

Supplemental Content

Support Center